

A

AGER D

Asymmetric oxidations – 3, 10
And would you like chirality with that? – Chirals Directory – 5, 38
Alleviating the problems of fitting a square peg in a round hole – 6, 38

ALBINI A.

Diastereoselective photosensitized radical addition to fumaric acid derivatives bearing oxazolidine auxiliary groups – Chirals Directory – 5, 43

ALDARF M.

Fungal biomass quantification and growth models. Special focus on solid-state culture: A mini-review – 4, 26

ALLEN P.

Customer Value Management: Five steps to creating customer value. Step 3: Create customer value – 1-2, 4

Customer Value Management: Five steps to creating customer value. Steps 4 and 5: Obtain customer feedback and improve customer value – 3, 2

ALPER S.

Fungal chitosan production from molasses – 3, 44

AMIN LAW

Legal news from Amin Law – 7-8, 32; 9, 12; 10, 60; 11-12, 46

AMRANE A.

Fungal biomass quantification and growth models. Special focus on solid-state culture: A mini-review – 4, 26

B

BACCALINI G.M.

We are back with forty years of experience – 10, 34

BADER R.

Protein processing generates both physiologically and pathologically important peptides – 11-12, 72

BASF

Contract manufacturing by BASF. Your expertise advantage (Company Profile) – 6, 25

BECKER & ASSOCIATES

Pharma Molecules – 3, 26; 5, 25; 9, 38; 10, 49

BERNARD Ph.

GPDBnet – A link between traditional knowledge and drug discovery – 10, 65

BIRINGER M.

High-throughput solid phase parallel synthesis of peptides in 96-well format – 7-8, 34

BLASER H.-U.

Highly active, easy to handle and stable palladium catalysts for C-C and C-N coupling reactions using aryl chlorides – 5, 29

BOCHAROVA I.V.

Antibacterial activity of the birch bark dry extract (BBDE) in experimental tuberculosis of mice – 9, 19

BOOGERS J.A.F.

Alleviating the problems of fitting a square peg in a round hole – 6, 38

BÖRNER A.

Homogeneous transition metal catalyzed enantioselective reductive amination – 5, 33

BOROLE Y.L.

Current status and emerging trends of Indian pharmaceutical industry, *Special on India*, 4

BRAUN R.

Biotech companies need patents – 9, 53

BROXTERMAN Q.B.

Towards breakthrough concepts in the industrial synthesis of di- and short oligopeptides – 11-12, 67

C

CAMPARI G.

Diastereoselective photosensitized radical addition to fumaric acid derivatives bearing oxazolidine auxiliary groups – Chirals Directory – 5, 43

CANSELIER J.P.

Emulsion preparation: Theoretical notions and practical aspects – 1-2, 16

CHASSAGNEUX E.

Preformulation and formulation development as tools for a good balance between time constraints and risks – 11-12, 26

CHASSIN, C.

Outlook for chemical and biochemical manufacturing – 1-2, 23

CHAUDHARI R.V.

Current status and emerging trends of Indian pharmaceutical industry, *Special on India*, 4

CHERNOUSOVA L.N.

Antibacterial activity of the birch bark dry extract (BBDE) in experimental tuberculosis of mice – 9, 19

CHISTYAKOV A.N.

Extract of the birch bark suppresses reproduction of the hepatitis C virus (HCV) in cells cultures and in infected mice – 3, 22

Antibacterial activity of the birch bark dry extract (BBDE) in experimental tuberculosis of mice – 9, 19

CHOPRA M.

Scale-up in bio-chemical processes – 1-2, 48

CHONSKI J.L.

Rapid preparation of pharmaceutical intermediates and targets using process intensification – 6, 8

CLASS S.

PharmaChem Horizons: 2004 Challenges and opportunities – 10, 42

COLAS A.

Silicone tubing for pharmaceuticals processing – 3, 30

CONICELLA F.

Business evaluation of biotechnology initiatives: from traditional methods to real options – 7-8, 12

COQUELET F.

GPDBnet – A link between traditional knowledge and drug discovery – 10, 65

CORIC P.

Vasopeptidases inhibitors of ACE, NEP and ECE – 7-8, 41

COX M.M.J.

Commercial production of proteins in insect cells – 1-2, 44

CREIGHTON L.

EU Reduced Test Package for notification of chemical intermediates with limited exposure – 6, 34

CUNTZE J.

World-class pharmaceutical materials from India, *Special on India*, 2

D

D&O PHARMACHEM

Company Profiles, 1

DAMEN E.

Rational Screening: Parallel Experimentation and Predictive Modeling applied to Chemical Process R&D – 4, 2

DANIELE A.

Business evaluation of biotechnology initiatives: from traditional methods to real options – 7-8, 12

DE VRIES A.H.M.

Alleviating the problems of fitting a square peg in a round hole – 6, 38

DE VRIES J.G.

Alleviating the problems of fitting a square peg in a round hole – 6, 38

DEBORSKI G.

Outsource or in-house? The evolving role of analytical services in pharmaceutical manufacturing – 9, 26

DEGUSSA – CREAVIS TECHNOLOGIES & INNOVATION

Catalysis Project House successfully concluded – 10, 90

DEGUSSA – SERVICE CENTER BIOCATALYSIS

Custom-tailored enzymes for all – 9, 57

DEL AMOR VILLA E.M.

Lipase catalysed synthesis of biotensides from renewable sources – 5, 18

DEMIKHOVA O.V.

Antibacterial activity of the birch bark dry extract (BBDE) in experimental tuberculosis of mice – 9, 19

DEPALMA A.

Peptide drugs: technology, science to the rescue. In the beginning – 7-8, 46

DERYABIN P.G.

Extract of the birch bark suppresses reproduction of the hepatitis C virus (HCV) in cells cultures and in infected mice – 3, 22

DHOTEL H.

Vasopeptidases inhibitors of ACE, NEP and ECE – 7-8, 41

DO Q.-T.

GPDBnet – A link between traditional knowledge and drug discovery – 10, 65

DÖMLING A.

Evolutionary multi-component reaction (MCR) chemistry provides a boon/boost to efficiency and diversity in drug discovery – 1-2, 32

E

ENFORS S.-O.

Recent advances on an electric silicon based chip for analysis of nucleic acids – 3, 6

ERÖS D.

Rational drug design and signal transduction therapy – 1-2, 27

EVOLVED NANOMATERIAL SCIENCES

Small tech-related products and services – Chirals Directory – 5, 41

F

F. HOFFMANN-LA ROCHE

DNA chips: Choosy fish hooks – 7-8, 18

Proteomics: seeing through the undergrowth – 9, 47

Targets for medicine – 11-12, 38

FAGNONI M.

Diastereoselective photosensitized radical addition to fumaric acid derivatives bearing oxazolidine auxiliary groups – Chirals Directory – 5, 43

FERNÁNDEZ-LAFUENTE R.

Solid-phase lipase engineering: a new tool in combinatorial biocatalysis – 9, 42

FIEDERLING N.

Hazardous materials and their properties – 1-2, 40

FIS FABBRICA ITALIANA SINTETICI

A resource for results, *Company Profiles*, 2

FLINN T.

Serving early drug development – 4, 16

FLYNGRIN CHRISTENSEN S.

Novel functional PEG resins and their applications – 11-12, 59

FMC LITHIUM

Organic intermediates from FMC, *Company Profiles*, inside back cover

FOURCADE F.

Fungal biomass quantification and growth models. Special focus on solid-state culture: A mini-review – 4, 26

FOURNIÉ-ZALUSKI M.C.

Vasopeptidases inhibitors of ACE, NEP and ECE – 7-8, 41

FROST & SULLIVAN

Intensified R&D spending by pharmaceutical companies to refill empty – 4, 8

China's accession to the WTO attracts foreign direct investment and increases competition – 5, 2



GABIG-CIMINSKA M.

Recent advances on an electric silicon based chip for analysis of nucleic acids – 3, 6

GALLER M.

The BPD – Some critical points – Biocides & Preservatives Directory – 10, 69

GOKSUNGUR Y.

Fungal chitosan production from molasses – 3, 44

GUISÁN J.M.

Solid-phase lipase engineering: a new tool in combinatorial biocatalysis – 9, 42

GULLIVER E.

Rapid preparation of pharmaceutical intermediates and targets using process intensification – 6, 8



HAMMOND S.

Successful outsourcing of pre-clinical drug discovery – 11-12, 47

HARSA S.

Fungal chitosan production from molasses – 3, 44

HATTON M.

LabWare - A LIMS for the enterprise – 11-12, 17

HERLAN G.

Synthesis information for active pharmaceutical ingredients on STN – 10, 26

HESSENIUS C.

High-throughput solid phase parallel synthesis of peptides in 96-well format – 7-8, 34

HIKAL

A leading partner of choice (Company Profile) – 11-12, 63; *Special on India*, 1

HOLT K.E.

Biocatalysis and chemocatalysis – A powerful combination for the preparation of enantiomerically pure α -amino acids – 9, 2

HOOGENRAAD M.

Rational Screening: Parallel Experimentation and Predictive Modeling applied to Chemical Process R&D – 4, 2



INGUIMBERT N.

Vasopeptidases inhibitors of ACE, NEP and ECE – 7-8, 41

INSTITUT ROSELL LALLEMAND

Company Profiles, 3

ISAEVA E.I.

Extract of the birch bark suppresses reproduction of the hepatitis C virus (HCV) in cells cultures and in infected mice – 3, 22

ISOCHEM

The nanotechnology boom – 6, 4

ISTITUTO NAZIONALE PER IL COMMERCIO ESTERO – ICE

The Italian Industry of intermediates and active pharmaceutical ingredients in a worldwide overview – 3, 17



KADYROV R.

Homogeneous transition metal catalyzed enantioselective reductive amination – 5, 33

KELLY M.

Evolved Nanomaterial Sciences separates the bad from the good – Chirals Directory – 5, 42

KÉRI G.

Rational drug design and signal transduction therapy – 1-2, 27

KERMANI F.

Re-energising Europharma – 11-12, 34

KING B.W.

High throughput HPLC: Sample security and traceability – 4, 10

KNIGHT D.J.

Preliminary risk assessment of biocides to help make commercial decisions – Biocides & Preservatives Directory – 10, 81

KRAUTER J.

Using homogeneous and heterogeneous catalysts – Enantioselective hydrogenation for organic synthesis – 10, 62

KREIT J.

Interest concerns of microbial cholesterol oxidase – 4, 20

KREUZER O.J.

High-throughput solid phase parallel synthesis of peptides in 96-well format – 7-8, 34



LEFÈVRE F.

Rapid development of novel biocatalysts for the manufacturing of chiral compounds – 9, 7

LEFORT L.

Alleviating the problems of fitting a square peg in a round hole – 6, 38

LEPEKHA L.N.

Antibacterial activity of the birch bark dry extract (BBDE) in experimental tuberculosis of mice – 9, 19

LERCH M.

Protein processing generates both physiologically and pathologically important peptides – 11-12, 72

LEUSCH H.-J.

The BPD – Some critical points – Biocides & Preservatives Directory – 10, 69

LOEHE T.

Purified water to cGMP – 10, 56

LUCANSKY P.

Effective project management... The key lean components in a regulated environment – 3, 38

LUCHTERS N.

Rational Screening: Parallel Experimentation and Predictive Modeling applied to Chemical Process R&D – 4, 2

LVOV D.K.

Extract of the birch bark suppresses reproduction of the hepatitis C virus (HCV) in cells cultures and in infected mice – 3, 22



MALCZEWSKI R.

Silicone tubing for pharmaceuticals processing – 3, 30

MATERIA

Materia. Catalysts for change, *Company Profiles*, 4

MAY O.

Amino acids: unnaturally, naturally! Hydantoinase process for manufacturing L- and D-amino acids – 7-8, 26

MCCARTHY N.

IMS highlights biotech as strong growth driver – 7/8, 8
Generics flourish as innovation stalls – 11-12, 10

MEGGLE

Meggle: Experts in excipients, *Company Profiles*, 5

MELLA M.

Diastereoselective photosensitized radical addition to fumaric acid derivatives bearing oxazolidine auxiliary groups – Chirals Directory – 5, 43

MITENI

Miteni's new pilot plant speeds fluorchemical development, *Company Profiles*, 6

MONTÉZIN M.

Rapid development of novel biocatalysts for the manufacturing of chiral compounds – 9, 7

MORBACH G.

High-throughput solid phase parallel synthesis of peptides in 96-well format – 7-8, 34

MORFLEX

Company Profiles, 7

MOSCA R.

Diastereoselective photosensitized radical addition to fumaric acid derivatives bearing oxazolidine auxiliary groups – Chirals Directory – 5, 43

MÜHLENWEG H.

Gas-phase reactions open up new roads to nanoproductions – 10, 86

MÜLLER

Ideas in mild steel, *Company Profiles*, 8

MYERS E.

Monthly status of the business of chemistry – 5, 6



NAGLER P.

Degussa Exclusive Synthesis maintains course in a difficult economic environment – 9, 14

NASH R.A.

Six Sigma approach to quality assurance in the pharmaceutical sector – 9, 32

NAUD F.

Highly active, easy to handle and stable palladium catalysts for C-C and C-N coupling reactions using aryl chlorides – 5, 29

NETTEKOVEN U.

Highly active, easy to handle and stable palladium catalysts for C-C and C-N coupling reactions using aryl chlorides – 5, 29



OLSON B.

Bayer Chemicals – Right what our customers need: Integrated forces for success – 1-2, 8

OREGON FREEZE DRY

Company Profiles, 9

ÖRFI L.

Rational drug design and signal transduction therapy – 1-2, 27

ORGAMOL

Orgamol – The Swiss fine chemical company, *Company Profiles*, 10



PALKA C.L.

How can you be a leader of change? – 10, 4
How can you transition successfully into your next role? – 11-12, 5

PALOMO J.M.

Solid-phase lipase engineering: a new tool in combinatorial biocatalysis – 9, 42

PELO R.

Worldwide pharmaceutical market trends and Japan's position – 5, 14

PESIC M.C.

Thymus therapy – 6, 16

PETERSEN A.

Synthesis information for active pharmaceutical ingredients on STN – 10, 26

PETRESA

Company Profile – 1-2, 14

PLASTIAPE

Plastiape: a leader with a lasting record of innovation and growth (Company Profile) – 11-12, 22
Company Profiles, 12

POLLAK P.

Outlook for chemical and biochemical manufacturing – 1-2, 23

In memory of Claude – 5, 11

PORAS H.

Vasopeptidases inhibitors of ACE, NEP and ECE – 7-8, 41

POSPELOV L.E.

Antibacterial activity of the birch bark dry extract (BBDE) in experimental tuberculosis of mice – 9, 19

POTAPCHUK L.

Effective project management... The key lean components in a regulated environment – 3, 38

POUX M.

Emulsion preparation: Theoretical notions and practical aspects – 1-2, 16

PRESNOVA G.A.

Extract of the birch bark suppresses reproduction of the hepatitis C virus (HCV) in cells cultures and in infected mice – 3, 22

Antibacterial activity of the birch bark dry extract (BBDE) in experimental tuberculosis of mice – 9, 19

Q**QUAEDFLIEG P.J.L.M.**

Towards breakthrough concepts in the industrial synthesis of di- and short oligopeptides – 11-12, 67

R**RAMOS M.**

Novel functional PEG resins and their applications – 11-12, 59

RAS E.-J.

Rational Screening: Parallel Experimentation and Predictive Modeling applied to Chemical Process R&D – 4, 2

RESEARCH AND MARKETS

Chiral technologies: commercial opportunities of today and the future – Chirals Directory – 5, 43

RIERMEIER T.H.

Homogeneous transition metal catalyzed enantioselective reductive amination – 5, 33

Using homogeneous and heterogeneous catalysts – Enantioselective hydrogenation for organic synthesis – 10, 62

RITZKE M.

High-throughput solid phase parallel synthesis of peptides in 96-well format – 7-8, 34

ROBIN Y.

Peptide synthesis and fine chemistry - Merging for progress – 11-12, 64

RODRIGUEZ C.

The BPD – A challenge for producers and formulators – Biocides & Preservatives Directory – 10, 79

ROHM AND HAAS

Ambersynth™ solid phase synthesis resins. Enhancing the art of therapeutic peptide synthesis – 7-8, 37

ROICE M.

Novel functional PEG resins and their applications – 11-12, 59

ROQUES B.P.

Vasopeptidases inhibitors of ACE, NEP and ECE – 7-8, 41

S**SABINSA**

Sabinsa Corporation. Our innovation is your answer, *Company Profiles*, 13

SAVE V.

World-class pharmaceutical materials from India, *Special on India*, 2

SCHEDER M.

Bayer Pharma Biotechnology: 30 years of experience now available to external clients – 7-8, 4

SCHMIDT J.

High-throughput solid phase parallel synthesis of peptides in 96-well format – 7-8, 34

SCHNYDER A.

Highly active, easy to handle and stable palladium catalysts for C-C and C-N coupling reactions using aryl chlorides – 5, 29

SCHWEPPE U.

Decision making in medicine – Utilizing digital support to ensure a rational decision making – 4, 14

SCIENTIFIC UPDATE

Highlights from "Modern Synthetic Methods: Reaction to Reality" – 7-8, 58

SENSUS

Company Profiles, 14

SHAH A.

Six Sigma approach to quality assurance in the pharmaceutical sector – 9, 32

SIFAVOR

Manufacturer of pharmaceutical active ingredients, *Company Profiles*, 15

SMIRNOVA T.N.

Antibacterial activity of the birch bark dry extract (BBDE) in experimental tuberculosis of mice – 9, 19

SONET J.-M.

Rapid development of novel biocatalysts for the manufacturing of chiral compounds – 9, 7

SONKE T.

Towards breakthrough concepts in the industrial synthesis of di- and short oligopeptides – 11-12, 67

SWIFT T.K.

Monthly status of the business of chemistry – 5, 6

T**TARAROV V.I.**

Homogeneous transition metal catalyzed enantioselective reductive amination – 5, 33

THOMMEN M.

Highly active, easy to handle and stable palladium catalysts for C-C and C-N coupling reactions using aryl chlorides – 5, 29

TUFTS UNIVERSITY

Nano-discovery, big idea – Chirals Directory – 5, 41

TURNER N.

Generics: moving up the value chain to higher priced products – 10, 38

U**ULMAN K.**

Silicone tubing for pharmaceuticals processing – 3, 30

V**VAN HEMMEN J.J.**

Worker exposure assessment for biocides: development of guidance – Biocides & Preservatives Directory – 10, 74

VERSPUI G.

Rational Screening: Parallel Experimentation and Predictive Modeling applied to Chemical Process R&D – 4, 2

W**WATSON W.**

Highlights from "Chiral Europe 2004", Part I – 10, 93; Part II – 11-12, 77

WEBER L.

Evolutionary multi-component reaction (MCR) chemistry provides a boon/boost to efficiency and diversity in drug discovery – 1-2, 32

WEGRZYN G.

Recent advances on an electric silicon based chip for analysis of nucleic acids – 3, 6

WICHMANN R.

Lipase catalysed synthesis of biotensides from renewable sources – 5, 18

WINKLER D.

High-throughput solid phase parallel synthesis of peptides in 96-well format – 7-8, 34

WOLTER A.

Drugs based on nucleic acids – 9, 22

WOOD A.

Outsource or in-house? The evolving role of analytical services in pharmaceutical manufacturing – 9, 26

Y**YENIDUNYA A.F.**

Fungal chitosan production from molasses – 3, 44

Z**ZAMBON GROUP**

Zambon Group: Continuous investments in R&D and innovation, *Company Profiles*, 16

ZERBE O.

Protein processing generates both physiologically and pathologically important peptides – 11-12, 72

ZIMMERMANN G.

Gas-phase reactions open up new roads to nanoproducts – 10, 86

ZINSSER, W.

CRISSEY – Automation platform for salt pre-screening and polymorph screening studies – 7-8, 55

INDEX

INDEX

INDEX

INDEX

INDEX

INDEX